Abstract
In this issue of Neuron, Ke etal.1 report a novel non-canonical interaction between 14-3-3θ and TDP-43 that impacts loss-of-function and gain-of-toxic pathology in TDP-43 proteinopathies. The authors further provide proof of principle for a 14-3-3θ-targeted gene therapy to reduce TDP-43-induced deficits in transgenic TDP-43 mutant mice.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have